Cargando…
Transcription factor POU4F2 promotes colorectal cancer cell migration and invasion through hedgehog‐mediated epithelial‐mesenchymal transition
As a POU homeodomain transcription factor, POU4F2 has been implicated in regulating tumorigenic processes in various cancers. However, the role of POU4F2 in colorectal cancer (CRC) remains unclear. Here, we revealed that POU4F2 functions as a tumor promotor in CRC. Bioinformatics analysis in specime...
Autores principales: | Guo, Kaibo, Wang, Peipei, Zhang, Leyin, Zhou, Yiwen, Dai, Xinyang, Yan, Yici, Chen, Yuxuan, Wasan, Harpreet S., Yu, Jieru, Ruan, Shanming, Sun, Leitao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486210/ https://www.ncbi.nlm.nih.gov/pubmed/34327778 http://dx.doi.org/10.1111/cas.15089 |
Ejemplares similares
-
Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors
por: Guo, Kaibo, et al.
Publicado: (2021) -
Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials
por: Zhang, Leyin, et al.
Publicado: (2021) -
Jiedu Sangen Decoction Inhibits Migration and Invasion of Colon Cancer SW480 Cells via Suppressing Epithelial Mesenchymal Transition
por: Zhang, Kai, et al.
Publicado: (2018) -
Inhibition to Epithelial-Mesenchymal Transition and Metastatic
Potential In Colorectal Cancer Cell By Combination of Traditional Chinese
Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor
por: Shan, Feiyu, et al.
Publicado: (2020) -
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
por: Sun, Leitao, et al.
Publicado: (2020)